We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA to Biosimilar Sponsors: Know Your (Analytical) Limits
FDA to Biosimilar Sponsors: Know Your (Analytical) Limits
Science has advanced enough that biosimilar sponsors can make a strong case for their product’s similarities to a reference product, but it’s going to be “critical” that sponsors understand the limits of their analytics, the FDA says in a new draft guidance document issued Tuesday.